Impact of inappropriate empirical antibiotic treatment on clinical outcomes of urinary tract infections caused by Escherichia coli: a retrospective cohort study

被引:17
|
作者
Zhu, Hongying [1 ]
Chen, Yanhui [1 ]
Hang, Yaping [1 ]
Luo, Hong [1 ]
Fang, Xueyao [1 ]
Xiao, Yanping [1 ]
Cao, Xingwei [1 ]
Zou, Shan [1 ]
Hu, Xiaoyan [1 ]
Hu, Longhua [1 ]
Zhong, Qiaoshi [1 ]
机构
[1] Nanchang Univ, Affiliated Hosp 2, Jiangxi Prov Key Lab Med, Clin Lab, Nanchang, Jiangxi, Peoples R China
基金
中国国家自然科学基金;
关键词
Inappropriate empirical antibiotic treatment; Urinary tract infection; Escherichia coli; Fluoroquinolones; CIPROFLOXACIN; GUIDELINES; THERAPY;
D O I
10.1016/j.jgar.2021.05.016
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: We aimed to determine the clinical impact of inappropriate empirical antibiotic treatment (IEAT) compared with appropriate empirical antibiotic treatment (AEAT) in hospitalised patients with urinary tract infections (UTIs) caused by Escherichia coli (E. coli). Methods: This retrospective cohort study included adult patients with a primary diagnosis of UTI who were treated with empirical antibiotics at a tertiary hospital in southern China over a 2-year period. Clinical data of patients who received IEAT were compared with those of patients receiving AEAT. We used multivariable logistic regression to identify the predictors for receiving IEAT and the risk factors affecting clinical outcomes. Results: A total of 213 patients were enrolled (median age, 61 years), of whom 103 (48.4%) received IEAT. IEAT was associated with empirical use of fluoroquinolones, male sex and age-adjusted Charlson comorbidity index (aCCI) score > 6. Hospital length of stay (LOS) was longer for patients who received IEAT than for those who received AEAT (13.6 +/- 8.6 days vs. 10.8 +/- 7.9 days; P = 0.008). IEAT was an independent risk factor for longer LOS along with aCCI score >= 2, lung disease and cardiac disease. Conclusion: Empirical use of fluoroquinolones for UTIs should be avoided, especially in male patients with aCCI score > 6. Improved empirical antimicrobial therapy may have a beneficial impact in reducing bacterial resistance and healthcare costs by decreasing the LOS. Therefore, interventions to promote indepth antibiotic stewardship programmes in China are needed. (C) 2021 Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.
引用
收藏
页码:148 / 153
页数:6
相关论文
共 50 条
  • [41] Economic Burden of Urinary Tract Infections From Antibiotic-Resistant Escherichia coli Among Hospitalized Adult Patients in Lebanon: A Prospective Cohort Study
    Iskandar, Katia
    Rizk, Rana
    Matta, Roula
    Husni-Samaha, Rola
    Sacre, Hala
    Bouraad, Etwal
    Dirani, Natalia
    Salameh, Pascale
    Molinier, Laurent
    Roques, Christine
    VALUE IN HEALTH REGIONAL ISSUES, 2021, 25 : 90 - 98
  • [42] Evaluating outcomes associated with revised fluoroquinolone breakpoints for Enterobacterales urinary tract infections: A retrospective cohort study
    Taylor M. Benavides
    James K. Aden
    Stephanie E. Giancola
    European Journal of Clinical Microbiology & Infectious Diseases, 2022, 41 : 741 - 749
  • [43] Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections. What antimicrobial to use?
    Elena Guajardo-Lara, Claudia
    Mario Gonzalez-Martinez, Pedro
    Jacobo Ayala-Gaytan, Juan
    SALUD PUBLICA DE MEXICO, 2009, 51 (02): : 157 - 161
  • [44] Microbial risk factors for treatment failure of pivmecillinam in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli
    Syre, Heidi
    Hetland, Marit Andrea Klokkhammer
    Bernhoff, Eva
    Bollestad, Marianne
    Grude, Nils
    Simonsen, Gunnar Skov
    Lohr, Iren Hoyland
    APMIS, 2020, 128 (03) : 232 - 241
  • [45] Monitoring fluoroquinolone resistance among ESBL-positive and ESBL-negative Escherichia coli strains isolated from urinary tract infections: An alert for empirical treatment
    Araujo, Max Roberto Batista
    Sant'Anna, Lincoln de Oliveira
    dos Santos, Nadir Nayara Carvalho
    Seabra, Luisa Ferreira
    dos Santos, Louisy Sanches
    REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2023, 56
  • [46] Impact of an antimicrobial stewardship program on urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli
    Esteve-Palau, Erika
    Grau, Santiago
    Herrera, Sabina
    Sorli, Luisa
    Montero, Milagro
    Segura, Concha
    Duran, Xavier
    Horcajada, Juan P.
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2018, 31 (02) : 110 - 117
  • [47] Antibiotic susceptibility pattern and ESBL prevalence in nosocomial Escherichia coli from urinary tract infections in Pakistan
    Ullah, Farhat
    Malik, Salman Akbar
    Ahmed, Jawad
    AFRICAN JOURNAL OF BIOTECHNOLOGY, 2009, 8 (16): : 3921 - 3926
  • [48] Phylogenetic Diversity, Antibiotic Resistance, and Virulence of Escherichia coli Strains from Urinary Tract Infections in Algeria
    Kara, Anfal
    Massaro, Chiara
    Giammanco, Giovanni M.
    Alduina, Rosa
    Boussoualim, Naouel
    ANTIBIOTICS-BASEL, 2024, 13 (08):
  • [49] Antibiotic prophylaxis and clinical outcomes among older adults with recurrent urinary tract infection: cohort study
    Ahmed, Haroon
    Farewell, Daniel
    Jones, Hywel M.
    Francis, Nick A.
    Paranjothy, Shantini
    Butler, Christopher C.
    AGE AND AGEING, 2019, 48 (02) : 228 - 234
  • [50] Clinical Impact of Ceftriaxone Resistance in Escherichia coli Bloodstream Infections: A Multicenter Prospective Cohort Study
    Tamma, Pranita D.
    Komarow, Lauren
    Ge, Lizhao
    Garcia-Diaz, Julia
    Herc, Erica S.
    Doi, Yohei
    Arias, Cesar A.
    Albin, Owen
    Saade, Elie
    Miller, Loren G.
    Jacob, Jesse T.
    Satlin, Michael J.
    Krsak, Martin
    Huskins, W. Charles
    Dhar, Sorabh
    Shelburne, Samuel A.
    Hill, Carol
    Baum, Keri R.
    Bhojani, Minal
    Greenwood-Quaintance, Kerryl E.
    Schmidt-Malan, Suzannah M.
    Patel, Robin
    Evans, Scott R.
    Chambers, Henry F.
    Fowler, Vance G., Jr.
    van Duin, David
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (11):